Alpha Tau Medical Stock (NASDAQ:DRTS)
Previous Close
$4.23
52W Range
$2.14 - $4.69
50D Avg
$3.84
200D Avg
$3.21
Market Cap
$353.78M
Avg Vol (3M)
$63.23K
Beta
1.07
Div Yield
-
DRTS Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AARD | Aardvark Therapeutics, Inc. Common Stock |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock |
| BLRX | BioLineRx Ltd. |
| CADL | Candel Therapeutics, Inc. |
| GALT | Galectin Therapeutics Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| REPL | Replimune Group, Inc. |
| ALDX | Aldeyra Therapeutics, Inc. |
| IMMP | Immutep Limited |